Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to ...

Nike shares surged 10 per cent in premarket trading on Friday as an encouraging... The S&P 500 Index may be on the cusp of a record high, but with earnings season... Exceptionally strong initial ...

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, ...

A new sport-utility vehicle launched by Xiaomi has drawn a rush of first-day orders. The sneaker and athletic apparel company expects the decline in its sales and margins to slow in the current ...

Health-care companies were more or less flat as traders rotated into higher risk sectors, amid optimism about Iran- and global trade negotiations. Walgreens Boots Alliance shares rose after it ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Novo Nordisk (NVO) is broadening patient access to its FDA-approved weight management drug, Wegovy (semaglutide) 2.4 mg, ...

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, ...

This article will be updated throughout the day, so check back often for more daily updates. Since tumbling into bear market ...

John Hyland outlines some of the top stories on the trading day on this rendition of Yahoo Finance's Market Minute. Micron ...